Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Pharming Group N.V (PHAR) Debt to Equity: 2019-2022

Historic Debt to Equity for Pharming Group N.V (PHAR) over the last 2 years, with Sep 2022 value amounting to $0.71.

  • Pharming Group N.V's Debt to Equity rose 35705.66% to $0.71 in Q3 2022 from the same period last year, while for Sep 2022 it was $0.71, marking a year-over-year increase of 431.96%. This contributed to the annual value of $0.00 for FY2021, which is 100.00% down from last year.
  • Latest data reveals that Pharming Group N.V reported Debt to Equity of $0.71 as of Q3 2022, which was up 93,704.59% from $0.00 recorded in Q2 2022.
  • Over the past 5 years, Pharming Group N.V's Debt to Equity peaked at $137.44 during Q4 2020, and registered a low of $0.00 during Q2 2022.
  • For the 3-year period, Pharming Group N.V's Debt to Equity averaged around $17.40, with its median value being $0.00 (2021).
  • Per our database at Business Quant, Pharming Group N.V's Debt to Equity surged by 40,870.32% in 2020 and then tumbled by 100.00% in 2021.
  • Over the past 4 years, Pharming Group N.V's Debt to Equity (Quarterly) stood at $0.34 in 2019, then spiked by 40,870.32% to $137.44 in 2020, then plummeted by 100.00% to $0.00 in 2021, then soared by 35,705.66% to $0.71 in 2022.
  • Its last three reported values are $0.71 in Q3 2022, $0.00 for Q2 2022, and $0.00 during Q1 2022.